Atricure names two new members to the board of directors

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage (laa) management, today announced that deborah h. telman and maggie yuen have been elected to its board of directors. ms. telman has spent over 20 years in senior executive roles at global companies. she is executive vice president and general counsel for organon (nyse: ogn), a global healthcare company formed in june 2021 through a spinoff from
ATRC Ratings Summary
ATRC Quant Ranking